What changed today in Aesthetics & Longevity: 2 trial updates, 1 new study
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 3 new official records on this desk today: 2 trial updates, 1 new study.
Why this matters
New clearances, safety communications and research in aesthetic and regenerative medicine affect what practices offer, how they describe it and what patients are told.
What changed
- Trial status changed to “Recruiting”: AWAKEN (Phase 2/3 Efficacy and Safety of PP405 in Adult Males)[1]
- New research in Clinical case reports: “Biosome Therapy for Androgenetic Alopecia in a Patient With Incomplete Response to Minoxidil and Finasteride: A Case Report”.[2]
- New trial registered: DEFINE (Dermal Evaluation of Facetem™ S in Nasolabial Folds Esthetics Improvement: DEFINE Study)[3]
- Also reported by Dermatology Times: “EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage”.[4]
- Also reported by American Med Spa Association: “Before You Raise Your Med Spa Marketing Budget, Look at Your Calendar”.[5]
Who this affects
- Med spas
- Medical directors
- Prescribers
- Practice owners & operators
- Pharmacies
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.
Update timeline
- First published.
- Added 2 new official records.

